Drug May Help Reverse Clotting Deficiency

By Amanda Gardner
HealthDay Reporter
Thursday, November 29, 2007; 12:00 AM

Copyright © 2007 ScoutNews, LLC. All rights reserved.

WEDNESDAY, Nov. 28 (HealthDay News) -- An experimental drug can boost the number of clotting cells, called platelets, in patients suffering from a dangerous deficiency of these cells, researchers report.

The new drug is called eltrombopag, and in one study, patients with the autoimmune disorder idiopathic thrombocytopenic purpura (ITP) were able to use the medication to boost their platelet levels and cut their risk for bleeding.

In a second study, patients with hepatitis C (HCV)-related cirrhosis of the liver were able to begin antiviral therapy for their condition after eltrombopag raised their platelet counts.

"Eltrombopag is not just used in one disease," explained Dr. John McHutchison, lead author of the hepatitis study and an associate director of the Duke Clinical Research Institute in Durham, N.C. "It could be used in cancer/chemotherapy, ITP; it could have a very, very broad use across many different diseases," said McHutchison, who is also professor of medicine at Duke University.

But the trials, both of which are published in the Nov. 29 issue of the New England Journal of Medicine, reported only short-term results and should be considered carefully, experts cautioned.

"I stress the preliminary nature of these reports," said Dr. Robert S. Schwartz, deputy editor of the New England Journal of Medicine and author of an accompanying editorial on the studies. "We thought that these preliminary results were promising, but they will have to be confirmed in bigger trials."

Thrombocytopenia, which refers to any disorder in which there are not enough platelets, can prevent people from receiving necessary treatments.

With ITP, the body destroys its own platelets or not enough platelets are produced.

"This is a condition in which there's a low platelet count, and if it drops very low, usually below 30,000, the clinical manifestations are principally bleeding and bruising," Schwartz explained.

Eltrombopag is thought to stimulate megakaryocytes, the bone marrow cells that produce blood platelets. The drug, also called Promacta, is being developed by GlaxoSmithKline, which funded both studies.